Drug Injection Devices to 2024
|発行||Greystone Research Associates||商品コード||281704|
The correlation between chronic conditions and the benefits of patient self-administration continues to influence therapeutic product decisions, managed care initiatives and regulatory actions. Drug injection device designs are increasingly being based on the results of human engineering inputs and patient preference research. Branding and packaging choices are more frequently being driven by data sources historically employed by consumer product marketers. For drug developers and device suppliers, the implications of these trends are influencing product development methodology and changing supply chain relationships. Decisions regarding as-supplied packaging that were once considered boilerplate have moved to the early stages of the development process.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
‘For the remainder of the decade, pipeline drugs and shifting demographics will drive sector growth as an aging population of baby boomers (23% of U.S. population) provides stimulus for industry demand. Currently, the over 65 segment accounts for approximately 13% of the U.S. population, with an estimated 40% of total healthcare expenditures, but by 2020, this segment is expected to grow to 17% of the population. This aging of the population will predominately benefit products that can be used by the elderly.'